Keensight Capital to Acquire a Majority Stake in Leading European CRO and CDMO, Symeres, from Gilde Healthcare Private Equity
5/25, 9:00 AM (Source: GlobeNewswire)
PARIS, May 25, 2021 (GLOBE NEWSWIRE)
Keensight Capital, one of the principal private equity managers dedicated to pan-European Growth Buyout investments, has reached an agreement to invest alongside management in Symeres, a leading European drug discovery Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO). According to the terms of the agreement, Keensight Capital will acquire a majority stake in Symeres from the Gilde Healthcare Private Equity fund, a leading European specialist healthcare investor.
Symeres is one of the largest European small molecule CRO & CDMOs, providing R&D services from preclinical drug discovery to Phase I and II clinical stage drug development and manufacturing to major pharmaceutical and bi
Gilde Healthcare
Gilde Healthcare Acquires Majority Stake in Danish Drug Development Consultancy KLIFO to Support International Growth Ambitions
Gilde Healthcare Acquires Majority Stake in Danish Drug Development Consultancy KLIFO to Support International Growth Ambitions
Northern European integrated drug development consultancy aims to further expand service offering and geographical footprint
UTRECHT, the Netherlands and COPENHAGEN, Denmark, May 06, 2021 (GLOBE NEWSWIRE) Gilde Healthcare, a specialized healthcare investor, and KLIFO A/S, a leading Northern European drug development consultancy with significant experience in partnering with biotech and pharmaceutical companies to advance their drug development projects, today announce that Gilde Healthcare’s Private Equity fund has acquired a majority stake in KLIFO. Gilde Healthcare aims to support KLIFO’s growth in the dynamically developing pharma outsourcing sector.
Northern European integrated drug development consultancy aims to further expand service offering and geographical footprintUTRECHT, the Netherlands and COPENHAGEN, Denmark, May 06, 2021 (GLOBE NEWSWIRE)
The Private Equity Fund of Gilde Healthcare Acquires German Medtech Company Acti-Med
• Investment to support the global expansion of leading manufacturer of precision medical components and devices
UTRECHT, The Netherlands and FREIENSTEINAU, Germany, April 27, 2021 (GLOBE NEWSWIRE) The Private Equity fund of Gilde Healthcare, a specialist healthcare investor, has acquired Acti-Med, a leading international developer and manufacturer of high-quality medical components and devices for the medical and pharmaceutical industries.
Founded in 1997, Germany-based Acti-Med focuses on tailor-made, highly-regulated, cannulas and cannula systems for pharmaceutical and medical applications, jointly developed with international Original Equipment Manufacturers (OEMs). Headquartered in Freiensteinau (Germany) and with operations in Kozerkí (Poland), Acti-Med has attracted clients from all around the world by combining the highest development and engineering capabilities, offering superior q
The Private Equity Fund of Gilde Healthcare Acquires German Medtech Company Acti-Med
• Investment to support the global expansion of leading manufacturer of precision medical components and devices
UTRECHT, The Netherlands and FREIENSTEINAU, Germany, April 27, 2021 (GLOBE NEWSWIRE) The Private Equity fund of Gilde Healthcare, a specialist healthcare investor, has acquired Acti-Med, a leading international developer and manufacturer of high-quality medical components and devices for the medical and pharmaceutical industries.
Founded in 1997, Germany-based Acti-Med focuses on tailor-made, highly-regulated, cannulas and cannula systems for pharmaceutical and medical applications, jointly developed with international Original Equipment Manufacturers (OEMs). Headquartered in Freiensteinau (Germany) and with operations in Kozerkí (Poland), Acti-Med has attracted clients from all around the world by combining the highest development and engineering capabilities, offering superio